A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506541-39-00

Acronym

20160323

Enrollment

118

Registered

2024-07-18

Start date

2018-08-03

Completion date

Unknown

Last updated

2026-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Cell Lung Cancer

None listed

Sex/Gender

All

Age

18 Years to No maximum

Austria, France, Germany, Netherlands, Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026